Compare VSAT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSAT | EVO |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 1.1B |
| IPO Year | 1996 | 2021 |
| Metric | VSAT | EVO |
|---|---|---|
| Price | $32.97 | $3.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $33.00 | $7.00 |
| AVG Volume (30 Days) | ★ 2.3M | 99.7K |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,582,796,000.00 | $887,396,457.00 |
| Revenue This Year | $5.23 | N/A |
| Revenue Next Year | $3.15 | $10.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.23 | N/A |
| 52 Week Low | $7.36 | $2.84 |
| 52 Week High | $43.59 | $5.10 |
| Indicator | VSAT | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 44.46 |
| Support Level | $29.13 | $2.89 |
| Resistance Level | $35.90 | $3.24 |
| Average True Range (ATR) | 2.58 | 0.09 |
| MACD | -0.30 | 0.04 |
| Stochastic Oscillator | 30.63 | 67.39 |
Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.